AgingResearch.NewsJoin free

AMO Pharma

CompanyUnited KingdomFounded 2015

Wikidata

AMO Pharma develops one asset, in phase 3 (AMO-02 in arrhythmogenic cardiomyopathy). Mostly small molecule acting on GSK3B; based in the United Kingdom, founded in 2015.

1
Asset
Furthest stage
Phase 3
0
Trials
2
Signals

Pipeline

1

  • AMO-02

    Inhibition of glycogen synthase kinase 3 beta (GSK3B).

    Phase 3, Small molecule, GSK3B, arrhythmogenic cardiomyopathy

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Signals2
  • Similar companies3

Intelligence